Novo Nordisk's New Weight-Loss Pill Approved

Novo Nordisks new weight-loss pill, a twenty-five milligram oral version of semaglutide, has been approved by the FDA. This approval comes at a crucial time for the company, following a challenging year with falling stock prices and competition. The pill, carrying the Wegovy brand name, showed promising results in a late-stage study, with participants losing an average of sixteen point six percent of their body weight. Approved for chronic weight management, this could widen access for millions and position Novo to tap into a massive global market. The race with Eli Lilly intensifies, offering more options for those battling weight issues and reshaping global obesity treatment.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.